JP2024507373A5 - - Google Patents
Info
- Publication number
- JP2024507373A5 JP2024507373A5 JP2023550647A JP2023550647A JP2024507373A5 JP 2024507373 A5 JP2024507373 A5 JP 2024507373A5 JP 2023550647 A JP2023550647 A JP 2023550647A JP 2023550647 A JP2023550647 A JP 2023550647A JP 2024507373 A5 JP2024507373 A5 JP 2024507373A5
- Authority
- JP
- Japan
- Prior art keywords
- treg
- population
- stimulant
- treg population
- culturing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163152787P | 2021-02-23 | 2021-02-23 | |
| US63/152,787 | 2021-02-23 | ||
| PCT/US2022/017526 WO2022182763A1 (en) | 2021-02-23 | 2022-02-23 | Methods for expanding regulatory t cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024507373A JP2024507373A (ja) | 2024-02-19 |
| JP2024507373A5 true JP2024507373A5 (https=) | 2025-03-04 |
Family
ID=83048425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023550647A Pending JP2024507373A (ja) | 2021-02-23 | 2022-02-23 | 制御性ｔ細胞を増殖させる方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240228962A9 (https=) |
| EP (1) | EP4297757A4 (https=) |
| JP (1) | JP2024507373A (https=) |
| CN (1) | CN116897201A (https=) |
| AU (1) | AU2022226163A1 (https=) |
| CA (1) | CA3206049A1 (https=) |
| WO (1) | WO2022182763A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024243552A1 (en) * | 2023-05-25 | 2024-11-28 | Board Of Regents, The University Of Texas System | Methods using st2 to identify patients for cancer therapy |
| WO2025096685A1 (en) * | 2023-10-30 | 2025-05-08 | City Of Hope | Methods of making and using regulatory t cells for treatment of autoimmune disorders and cancers |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005206746B2 (en) * | 2004-01-08 | 2008-08-28 | Regents Of The University Of California | Regulatory t cells suppress autoimmunity |
| WO2011126806A1 (en) * | 2010-04-08 | 2011-10-13 | The Trustees Of The University Of Pennsylvania | Methods to expand a t regulatory cell master cell bank |
| US9018006B2 (en) * | 2010-07-23 | 2015-04-28 | The University Of Toledo | Stable Tregs and related materials and methods |
| JP6422344B2 (ja) * | 2012-03-02 | 2018-11-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 同種抗原反応性の制御性ｔ細胞を増大させる方法 |
| US10093901B2 (en) * | 2013-05-10 | 2018-10-09 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Use of specific regulatory T-cells to induce immune tolerance |
| WO2018106885A1 (en) * | 2016-12-07 | 2018-06-14 | East Carolina University | Compositions and methods for in vitro cultivation and/or expansion of regulatory t cells |
| US20190367876A1 (en) * | 2017-01-18 | 2019-12-05 | F1 Oncology, Inc. | Methods of transducing and expanding immune cells and uses thereof |
| US11827705B2 (en) * | 2017-03-28 | 2023-11-28 | The Trustees Of The University Of Pennsylvania | Methods to protect transplanted tissue from rejection |
| US10842815B2 (en) * | 2017-06-16 | 2020-11-24 | Stemspine Llc | Perispinal perfusion by administration of T regulatory cells alone or in combination with angiogenic cell therapies |
| US12233094B2 (en) * | 2017-11-29 | 2025-02-25 | Spinalcyte, Llc | Interaction of fibroblasts and immune cells for activation and uses thereof |
| CN112839671A (zh) * | 2018-05-17 | 2021-05-25 | 明尼苏达大学董事会 | 抗药性免疫细胞及其使用方法 |
| BR112021014442A2 (pt) * | 2019-02-01 | 2021-09-21 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imunoterapia aprimorada |
-
2022
- 2022-02-23 WO PCT/US2022/017526 patent/WO2022182763A1/en not_active Ceased
- 2022-02-23 CA CA3206049A patent/CA3206049A1/en active Pending
- 2022-02-23 EP EP22760340.4A patent/EP4297757A4/en active Pending
- 2022-02-23 US US18/547,627 patent/US20240228962A9/en active Pending
- 2022-02-23 AU AU2022226163A patent/AU2022226163A1/en active Pending
- 2022-02-23 CN CN202280016734.1A patent/CN116897201A/zh active Pending
- 2022-02-23 JP JP2023550647A patent/JP2024507373A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025011150A (ja) | ガンマ－デルタｔ細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 | |
| Aubert et al. | Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection | |
| Putnam et al. | Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation | |
| Ross et al. | Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation | |
| CN103930130B (zh) | 抗第三方中央型记忆t细胞、其产生方法以及其在移植和疾病治疗中的应用 | |
| CN103898051B (zh) | 提高免疫反应性的方法 | |
| Paczesny et al. | Acute graft-versus-host disease: new treatment strategies | |
| Saito et al. | Safety and tolerability of allogeneic dendritic cell vaccination with induction of Wilms tumor 1–specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: a case report and review of the literature | |
| KR20240043810A (ko) | 세포 치료에 사용하기 위한 면역학적으로 식별 가능한 세포 표면 변이체 | |
| TW201819628A (zh) | 使用具有工程化穩定表現內源性foxp3基因之cd4 t細胞治療自體免疫疾病的方法 | |
| US12569516B2 (en) | Subject-specific tumor inhibiting cells and the use thereof | |
| JP2024507373A5 (https=) | ||
| US20230279352A1 (en) | Methods for generating primary immune cells | |
| JP2025514745A5 (https=) | ||
| EP2702145A1 (en) | Methods for preparing accessory cells and uses thereof for preparing activated nk cells | |
| Kauke-Navarro et al. | Novel strategies in transplantation: genetic engineering and vascularized composite allotransplantation | |
| JP2022023136A5 (https=) | ||
| US20240226168A1 (en) | Engineered nk cells and uses thereof | |
| US9783616B2 (en) | Regulating transplant rejection of donor and embryonic stem cell-derived tissues and organs | |
| Jiang et al. | CD4+ CD25+ regulatory T cells are not required for mesenchymal stem cell function in fully MHC-mismatched mouse cardiac transplantation | |
| JP2019508056A5 (https=) | ||
| AU2024224895A1 (en) | Methods for generating primary immune cells | |
| Matar et al. | Cellular immunotherapies in preclinical large animal models of transplantation | |
| EP4257676A1 (en) | Modified immune cell and use thereof | |
| WO2013076245A1 (en) | Allogeneic immune response control |